Takeda’s Alunbrig shows promise as first-line ALK NSCLC therapy
admin 26th September 2018 Uncategorised 0Takeda’s Alunbrig cut the risk of disease progression or death by more than 50% compared to Pfizer’s Xalkori in adults with ALK+ non-small cell lung cancer.
More: Takeda’s Alunbrig shows promise as first-line ALK NSCLC therapy
Source: News